Key Safety Differentiators No IGF-1 elevation: AOD-9604 does not stimulate IGF-1, meaning it avoids risks such as organ/tissue overgrowth or acromegaly No glucose disruption: Clinical data shows it does not impair insulin sensitivity or worsen blood sugar regulation Comparable to placebo: In obesity trials, the incidence of adverse effects was similar to placebo groups, underscoring its tolerability Legal Status of AOD-9604 United States: AOD-9604 is not FDA-approved as a drug, dietary supplement, or weight loss therapy
Whether you're an active individual striving for peak performance or simply seeking a holistic approach to maintaining your health, Vitamin Injections can be a valuable addition to your wellness routine
Early body composition changes, such as reduced waist circumference or modest fat loss, often become apparent by weeks 2-4
I can already see the result
The Bigger Concern: Leaving a Deficiency Untreated When weighing the minimal risks of B12 injections, it helps to consider the well-documented risks of an untreated B12 deficiency
